Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence
Status:
Unknown status
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This study will test the safety and efficacy of the PROMETA® Treatment Protocol (which
includes the benzodiazepine antagonist flumazenil) in reversing the neurocognitive impairment
and this in turn will lead to improved ability to resist alcohol related cues and enhance
involvement in psychosocial treatment.